1. Home
  2. RIGL vs TATT Comparison

RIGL vs TATT Comparison

Compare RIGL & TATT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • TATT
  • Stock Information
  • Founded
  • RIGL 1996
  • TATT 1985
  • Country
  • RIGL United States
  • TATT Israel
  • Employees
  • RIGL N/A
  • TATT N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • TATT Aerospace
  • Sector
  • RIGL Health Care
  • TATT Industrials
  • Exchange
  • RIGL Nasdaq
  • TATT Nasdaq
  • Market Cap
  • RIGL 298.0M
  • TATT 308.2M
  • IPO Year
  • RIGL 2000
  • TATT 1987
  • Fundamental
  • Price
  • RIGL $17.28
  • TATT $27.03
  • Analyst Decision
  • RIGL Buy
  • TATT Strong Buy
  • Analyst Count
  • RIGL 5
  • TATT 1
  • Target Price
  • RIGL $36.80
  • TATT $35.00
  • AVG Volume (30 Days)
  • RIGL 222.1K
  • TATT 146.6K
  • Earning Date
  • RIGL 05-06-2025
  • TATT 05-21-2025
  • Dividend Yield
  • RIGL N/A
  • TATT N/A
  • EPS Growth
  • RIGL N/A
  • TATT 96.08
  • EPS
  • RIGL 0.99
  • TATT 1.00
  • Revenue
  • RIGL $179,278,000.00
  • TATT $152,116,000.00
  • Revenue This Year
  • RIGL $12.53
  • TATT $18.62
  • Revenue Next Year
  • RIGL $15.68
  • TATT $10.62
  • P/E Ratio
  • RIGL $17.36
  • TATT $32.84
  • Revenue Growth
  • RIGL 54.71
  • TATT 33.68
  • 52 Week Low
  • RIGL $7.48
  • TATT $11.03
  • 52 Week High
  • RIGL $29.82
  • TATT $33.83
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 44.84
  • TATT 48.72
  • Support Level
  • RIGL $16.05
  • TATT $26.20
  • Resistance Level
  • RIGL $17.52
  • TATT $33.83
  • Average True Range (ATR)
  • RIGL 1.26
  • TATT 2.29
  • MACD
  • RIGL 0.10
  • TATT 0.15
  • Stochastic Oscillator
  • RIGL 63.57
  • TATT 31.10

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About TATT TAT Technologies Ltd.

TAT Technologies Ltd provides solutions and services to the commercial and military aerospace and ground defense industries, focused mainly on three product areas and services: Thermal Management, Power and Actuation, and Maintenance, Repair and Overhaul (MRO). Its product portfolio includes heat exchangers, cooling systems, and mechanical aircraft accessories and systems such as pumps, valves, and turbine power units. Its operating segments are MRO services for aviation components, which derive key revenue, Original equipment manufacturing (OEM) of heat transfer solutions and aviation accessories, MRO services for heat transfer components and OEM of heat transfer solutions, and Overhaul and coating of jet engine components. Geographically, it derives key revenue from the United States.

Share on Social Networks: